---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-039357"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2022-02-14T23:59:59+00:00"
generated_at: "2026-06-27T08:24:25.580312+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO RGX-314 Phase II ALTITUDE: 47% patients achieve ≥2-step DRSS improvement at 6 months vs 0% control

## Summary
- 47% of RGX-314 patients in Cohort 1 showed ≥2-step DRSS improvement at 6 months vs 0% control; up from 33% at 3 months.
- No drug-related serious adverse events or intraocular inflammation in 15 patients at 6 months; therapy well tolerated.
- Among NPDR patients (severity 47-53), 57% achieved ≥2-step improvement; among PDR patients, 38% achieved improvement.
- Enrollment ongoing for Cohorts 2 (5x10^11 GC/eye) and 3 (NAb-positive patients) with no prophylactic corticosteroid use.

## SEC filing metadata
- accession: 0001193125-22-039357
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2022-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312522039357/0001193125-22-039357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312522039357/d312888d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-039357
- JSON: https://secwatch.observer/filing/0001193125-22-039357.json
- Plain text: https://secwatch.observer/filing/0001193125-22-039357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.